JAGSNPHARM Jagsonpal Pharmaceuticals Ltd Earnings Reports Announcement 2025 - FY25 Earnings Report Jagsonpal Pharmaceuticals reports a 28.8% revenue growth to 2,687 million and a 59% increase in operating EBITDA to 579 million for FY25, with a proposed 125% dividend per share. The announcement is dated May 6, 2025, covering the fiscal year ending March 31, 2025..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Jagsonpal Pharmaceuticals Ltd